Dana-Farber Research Supports FDA Approval of New Therapy for Metastatic Breast Cancer
February 16th 2023Sacituzumab govitecan, a novel antibody drug-conjugate therapy has been granted accelerated approved by the U.S. Food and Drug Administration for the treatment of metastatic HR+, HER2- breast cancer.
Read More
In an internationally conducted clinical trial lead by Dana-Farber involving patients with recurrent ovarian cancer that is resistant to platinum therapy, a novel conjugate therapy called mirvetuximab soravtansine resulted in substantially better responses than standard treatments.
Read More
Three-Drug Combination Therapy Effective in Patients with High-Risk CLL, Trial Shows
February 1st 2023A three-drug combination that sent chronic lymphocytic leukemia into deep remissions in a broad group of patients in a clinical trial is highly effective in patients with high-risk forms of the disease, a new, phase 2 clinical trial led by Dana-Farber Cancer Institute investigators indicates.
Read More
CAR-T-cell Shows Promise in Patients With Lymphoma of the Brain and Spinal Cord in Early Trial
January 24th 2023A CAR-T-cell therapy known as axicabtagene ciloleucel is safe and shows encouraging signs of efficacy in a small pilot trial involving patients with lymphoma of the brain and/or spinal cord.
Read More
Paper Proposes New Community-Oriented Fellowship Training Model for Hematologists/Oncologists
December 22nd 2022As patients with cancer increasingly receive treatment in community hospitals and clinics and many such centers experience a shortage of oncologists, a group of physicians at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, and Harvard Medical School has proposed the first-ever training blueprint for oncologists planning careers in a community or academic-community setting.
Read More
Scientists Map Genetic Evolution of Chronic Lymphocytic Leukemia to Richter Syndrome
December 21st 2022In a new study, scientists reveal for the first time the genomic differences between chronic lymphocytic leukemia and Richter's, the molecular pathways by which Richter's emerges, and the existence of multiple subtypes of the disease.
Read More
New Clinical Tool for Clonal Hematopoiesis Identifies Patients at High Risk for Blood Cancer
December 14th 2022A new clinical tool developed by a team of researchers led by the Dana-Farber Cancer Institute pinpoints which clonal hematopoiesis patients are at highest risk for cancer progression.
Read More
Dana-Farber Research Supports FDA Approval of New Therapy for Certain Patients With Ovarian Cancer
November 23rd 2022Mirvetuximab soravtansine has been granted accelerated approval by the U.S. Food and Drug Administration on November 14 for the treatment of recurrent platinum-resistant high-grade serous ovarian cancer that highly expresses folate receptor alpha.
Read More
Dana-Farber Cancer Institute, one of the world’s leading cancer research and treatment centers, has partnered with the Parker Institute for Cancer Immunotherapy, the leading network of immuno-oncology expertise in the world, as a member of the PICI Network with a goal to better understand the tumor microenvironment across cancer types and translate these basic discoveries to the clinic as impactful cancer immunotherapies.
Read More
Dana-Farber Cancer Institute and Lifespan Renew Strategic Alliance Agreement
May 2nd 2022Dana-Farber Cancer Institute and the Lifespan Cancer Institute have agreed to renew their strategic alliance to advance cancer treatment and research. Dana-Farber and the Lifespan Cancer Institute signed an initial agreement in 2017.
Read More